Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ: IMUX), discusses the company's encouraging first-quarter performance with Proactive.

The company presented positive data from a clinical trial at the Digestive Disease Week conference, showcasing the first clinical proof of concept for their molecule 856 in patients with celiac disease, targeting the renewal of the gut barrier function and tissue, eliminating the need for immunosuppressive effects.

Additionally, the company has sufficient funding until the fourth quarter of 2024.

Immunic expects first interim data from their phase two study in progressive MS later this year, further bolstering their overall MS strategy.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com